Real-world experience in reducing relapse rate of Neuromyelitis Optica Spectrum Disorder with first-generation anti-CD20 monoclonal antibody: A single-center study in Manila, Philippines

Key Points

• Relapse rate reduction was achieved with first-generation anti-CD20 monoclonal antibody treatment.
• Overall findings suggest a meaningful decrease in disease activity when using this therapeutic approach.
• This observational analysis of a single-center study shows promising results regarding disease management.
• Continued research is essential to validate these findings and broaden the evidence base.